In-hospital prevalence of mucormycosis among coronavirus disease 2019 (COVID-19) patients and COVID-19 in mucormycosis: a systematic review and meta-analysis

Int Forum Allergy Rhinol. 2022 Mar;12(3):313-317. doi: 10.1002/alr.22906. Epub 2021 Oct 11.

Authors

Akansha Sinha^{1

2}, Sonu Menachem Maimonides Bhaskar^{1

2

3

4}

Affiliations

¹ University of New South Wales (UNSW), South Western Sydney Clinical School, Liverpool, NSW, Australia.
² Neurovascular Imaging Laboratory, Clinical Sciences Stream, Ingham Institute for Applied Medical Research, Sydney, NSW, Australia.
³ NSW Brain Clot Bank, NSW Health Pathology, Sydney, NSW, Australia.
⁴ Department of Neurology and Neurophysiology, Liverpool Hospital and South Western Sydney Local Health District, Sydney, NSW, Australia.

No abstract available

Keywords: COVID-19; SARS-CoV2; cerebrovascular disease; global health; infectious disease; meta-analysis; mucormycosis; public health.

Publication types

Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review

MeSH terms

COVID-19*
Hospitals
Humans
Mucormycosis* / diagnosis
Mucormycosis* / epidemiology
Prevalence
SARS-CoV-2